dpp-4 inhibitor and glp-1 receptor agonist combination not recommended guideline Complete pharmacology pharmacotherapy of inhibitors in bullet points for easy understanding: DPP-4 Inhibitors –Summary 1. Drug Names (Generic / Brand) Sitagliptin – Januvia Saxagliptin – Onglyza Linagliptin – Tradjenta Alogliptin – SGLT2 Inhibitors and GLP-1 Receptor

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once

GLP-1 secretion is stimulated by nutrient intake and exerts its effects on glucose homeostasis by stimulating insulin secretion, gastric emptying confiding the food intake, and -cell proliferation